GABRD
ENSG00000187730
Target class
Ion channel
Chromosome
1
Approved drugs
55
Clinical candidates (approved and in development)
67
- Approved drugs
- 55
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 67
- Chemical probe available
- No
- Other names
- GABAARdelta
- Target name
- GABRD
- Gene name
- Gamma-aminobutyric acid type A receptor subunit delta
- Gene symbol
- GABRD
- Protein name
- Gamma-aminobutyric acid receptor subunit delta (GABA(A) receptor subunit delta) (GABAAR subunit delta)
- Gene biotype
- Protein coding
- Gene family
- Gamma-aminobutyric acid type A receptor subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 18
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 538.42
- Tissue specificity (Gini)
- 0.911
- Tissue specificity (tau)
- 0.966
- KEGG gene identifiers
- hsa:2563
- Protein interaction confidence
- 0.82264
- Protein interaction partners
- 25
- End position
- 2030758
- Start position
- 2019329
- Chromosome
- 1
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 35355020
- Tissue specificity (tau)
- 0.966462
- Expression inequality (Gini)
- 0.911482
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 538.42
- Brain - Cerebellum
- 516.96
- Brain - Frontal Cortex (BA9)
- 104.87
- Brain - Cortex
- 95.28
- Brain - Nucleus accumbens (basal ganglia)
- 54.42
Expression in transcripts per million
- Brain - Cerebellar Hemisphere538.42
- Brain - Cerebellum516.96
- Brain - Frontal Cortex (BA9)104.87
- Brain - Cortex95.28
- Brain - Nucleus accumbens (basal ganglia)54.42
- Brain - Anterior cingulate cortex (BA24)46.4
- Brain - Caudate (basal ganglia)41.37
- Brain - Putamen (basal ganglia)30.59
- Brain - Amygdala20.27
- Brain - Hippocampus10.63
- Testis8.85
- Brain - Substantia nigra4.04
- Pituitary3.35
- Brain - Hypothalamus3.04
- Brain - Spinal cord (cervical c-1)1.83
- Thyroid1.55
- Lung1.21
- Adrenal Gland1.04
- Breast - Mammary Tissue0.72
- Skin - Not Sun Exposed (Suprapubic)0.67
- Skin - Sun Exposed (Lower leg)0.59
- Artery - Coronary0.56
- Adipose - Subcutaneous0.46
- Artery - Aorta0.45
- Esophagus - Mucosa0.44
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0007214
- GO:1902476
Cellular components
- GO:0005886
- GO:0004890
- GO:0005515
Related records
Trials (3,891)
- "Chou's Tiaoshen" Acupoints for Short-term Insomnia.
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
- 1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia
- 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
- 50% Effective Concentration of Sevoflurane for Immobility
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A Better Choice for Patients Undergoing Endovascular Coil Embolization
- A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
- A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS
Drugs (77)
- ABP-700 GABA-A receptor; anion channel agonist
- Acamprosate GABA-A receptor; anion channel positive modulator
- Acamprosate calcium GABA-A receptor; anion channel positive modulator
- Adipiplon GABA-A receptor; anion channel partial agonist
- Alprazolam GABA-A receptor; anion channel positive allosteric modulator
- Brexanolone GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
- Butalbital GABA-A receptor; anion channel positive allosteric modulator
- Cenobamate GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
- Cipepofol GABA-A receptor; anion channel agonist
- Clobazam GABA-A receptor; anion channel positive allosteric modulator
- Clomethiazole GABA-A receptor; anion channel positive allosteric modulator
- Clonazepam GABA-A receptor; anion channel positive allosteric modulator
- Clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acid GABA-A receptor; anion channel positive allosteric modulator
- Clotiazepam GABA-A receptor; anion channel positive allosteric modulator
- Darigabat GABA-A receptor; anion channel agonist